Search results for " type 1"

showing 10 items of 430 documents

Glycated serum proteins and glucose tolerance

1988

Glycated serum proteins (GSP), stable glycated hemoglobin (HbA1c) together with some metabolic parameters were evaluated in 120 subjects, 30 with normal glucose tolerance (NGT), 30 with impaired glucose tolerance (IGT), 30 with non-insulin-dependent diabetes mellitus (NIDD), and 30 with insulin-dependent diabetes mellitus (IDD). GSP levels were significantly higher in IGT, NIDD and IDD than in NGT. HbA1c levels were not significantly higher in IGT in comparison with NGT, but were significantly higher in NIDD and in IDD than in NGT and IGT. GSP correlated better than HbA1c with all metabolic parameters considered. Taking into account the distribution of the values, GSP showed a smaller overl…

AdultBlood GlucoseMalemedicine.medical_specialtyGlycosylationendocrine system diseasesEndocrinology Diabetes and MetabolismImpaired glucose toleranceHba1c levelchemistry.chemical_compoundEndocrinologystomatognathic systemReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansTriglyceridesGlycated HemoglobinGlucose tolerance testmedicine.diagnostic_testbusiness.industryCholesterolnutritional and metabolic diseasesBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood proteinsCholesterolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2chemistryHyperglycemiaMetabolic control analysisFemaleGlycated hemoglobinbusinesshormones hormone substitutes and hormone antagonistsActa Diabetologica Latina
researchProduct

Evaluation of CGMS® During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes

2006

CGMS (Medtronic Minimed, Duesseldorf, Germany) allows continuous glucose monitoring. Recent studies with invasive monitoring techniques revealed discrepancies in blood glucose measurements obtained from different anatomical sites compared with those from the fingertip. The aim of this study was to investigate the CGMS and a device for alternative site testing (AST) during dynamic blood glucose changes and to compare these results with fingertip measurements.Twelve patients with type 1 diabetes (seven women, five men; age, 33.3 +/- 8.7 years) received a 75-g oral glucose load. Insulin was applied intravenously (rapid glucose decline) or subcutaneously (moderate glucose decline) in a dosage b…

AdultBlood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyForearmDiabetes mellitusmedicineHumansHypoglycemic AgentsInsulinIn patientBlood Glucose MeasurementType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringSite testingInsulinGlucose MeasurementMiddle Agedmedicine.diseaseSurgeryMedical Laboratory TechnologyDiabetes Mellitus Type 1medicine.anatomical_structureAnesthesiaInjections IntravenousFemalebusinessDiabetes Technology & Therapeutics
researchProduct

Polymorphonuclear leukocyte membrane fluidity and cytosolic Ca2+ concentration in diabetes mellitus.

1998

We evaluated polymorphonuclear membrane (PMN) fluidity in 32 subjects with type 1 diabetes mellitus, 38 subjects with type 2 diabetes mellitus and 38 normal control subjects, by marking intact and unstimulated PMN cells with the fluorescent probe 1-[4-(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene (TMA-DPH). We also evaluated PMN cytosolic Ca2+ content by marking intact and unstimulated PMN cells with the fluorescent probe Fura 2-AM. PMN membrane fluidity differentiated normal subjects from type 1 and 2 diabetic subjects. The PMN cytosolic Ca2+ concentration did not discriminate type 1 and 2 diabetic subjects from normal control subjects. No statistical correlation was found between PMN …

AdultBlood GlucoseMalemedicine.medical_specialtyMembrane FluidityNeutrophilsEndocrinology Diabetes and MetabolismNeutrophilechemistry.chemical_elementCalciumchemistry.chemical_compoundEndocrinologyCytosolReference ValuesDiabetes mellitusInternal medicineInternal MedicinemedicineMembrane fluidityHumansTriglyceridesFluorescent DyesGlycated HemoglobinType 1 diabetesCholesterolType 2 Diabetes Mellitushemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseaseCytosolEndocrinologyCholesterolDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2CalciumFemaleFura-2Acta diabetologica
researchProduct

Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection.

2013

Background: An important task in diabetes management is detection of hypoglycemia. Professional continuous glucose monitoring (CGM), which produces a glucose reading every 5 min, is a powerful tool for retrospective identification of unrecognized hypoglycemia. Unfortunately, CGM devices tend to be inaccurate, especially in the hypoglycemic range, which limits their applicability for hypoglycemia detection. The objective of this study was to develop an automated pattern recognition algorithm to detect hypoglycemic events in retrospective, professional CGM. Method: Continuous glucose monitoring and plasma glucose (PG) readings were obtained from 17 data sets of 10 type 1 diabetes patients und…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringHypoglycemiaSensitivity and SpecificityAutomationDiabetes managementBlood Glucose Self-MonitoringDiabetes mellitusInternal MedicineMedicineHumansIntensive care medicineGlycemicMonitoring PhysiologicRetrospective StudiesType 1 diabetesbusiness.industryContinuous glucose monitoringBlood Glucose Self-Monitoringnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Original ArticlebusinessAlgorithmsJournal of diabetes science and technology
researchProduct

Physical activity does not inevitably improve quality of life in young adults with type 1 diabetes

2016

Relationships between exercise, glucose control and diabetes dependent quality of life (DDQoL) are not straightforward. We investigated the DDQoL of 99 persons with type 1 diabetes and linked it to individual amount of weekly physical activity and HbA1c. Physically active lifestyle was not associated with better DDQoL or glucose control.

AdultBlood GlucoseMaleyoung adultsmedicine.medical_specialtyquality of life questionnaireGlucose controlEndocrinology Diabetes and MetabolismPhysical activityphysical activity030209 endocrinology & metabolism03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyQuality of life (healthcare)Diabetes mellitusSurveys and QuestionnairesInternal MedicinemedicineHumans030212 general & internal medicineYoung adultta315Life StyleRetrospective StudiesGlycated HemoglobinType 1 diabetesexercisebusiness.industryta3141General Medicinemedicine.diseaseDiabetes Mellitus Type 1Physical therapyQuality of LifeFemalebusinessDiabetes Research and Clinical Practice
researchProduct

The effects of equal caloric amounts of xylitol, sucrose and starch on insulin requirements and blood glucose levels in insulin-dependent diabetics

1981

Xylitol has been suggested as a potentially useful sweetener in the diabetic diet. In 14 insulin-dependent diabetics a standard diabetic diet regimen was compared with diets in which starch was isocalorically exchanged in the breakfast meal by either 30 g xylitol or 30 g sucrose. Insulin requirement and blood glucose were measured using a glucose-controlled insulin infusion system. The results following breakfast with xylitol were similar to those after starch breakfasts. Sucrose, in contrast, induced a greater post-prandial rise in blood glucose levels despite counter-regulation by the glucose-controlled insulin infusion system. Insulin requirement after sucrose significantly exceeded (p l…

AdultBlood GlucoseSucroseSucroseStarchEndocrinology Diabetes and Metabolismmedicine.medical_treatmentXylitolArtificial pancreaschemistry.chemical_compoundDiabetes mellitusDietary CarbohydratesInternal MedicinemedicineHumansInsulinFood scienceXylitolMealC-PeptideChemistryInsulindigestive oral and skin physiologyfood and beveragesStarchmedicine.diseasecarbohydrates (lipids)Diabetes Mellitus Type 1Diabetic dietEnergy IntakeDiabetologia
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

2008

BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Glargine is associated with reduced frequency of hypoglycemic episodes (mostly nocturnal) as well as effective glycemic control. Maintenance of good metabolic control before conception and throughout pregnancy is essential to lower the risk of fetal malformations. Glargine might be a valuable alternative in the management of pregnancies complicated by diabetes mellitus. However, because its clinical utility has not been established, the use of glargine is not currently recommended during pregnancy. OBJECTIVE: The aim of this study was to retrospectively evaluat…

AdultBlood Glucosemedicine.medical_specialtyInsulin IsophanePregnancy in DiabeticsInsulin GlargineSettore MED/13 - EndocrinologiaInsulin aspartPregnancyDiabetes mellitusInternal medicinemedicineOutpatient clinicInsulin lisproHumansHypoglycemic AgentsInsulinPharmacology (medical)Body Weights and MeasuresFemurInsulin AspartGlycemicRetrospective StudiesPharmacologyGlycated HemoglobinType 1 diabetesPregnancyInsulin LisproInsulin glarginebusiness.industryglargine type 1 diabetesPregnancy Outcomemedicine.diseaseInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Case-Control StudiesFemalebusinessmedicine.drugClinical therapeutics
researchProduct

Cytosolic Ca2+Content and Membrane Fluidity of Platelets and Polymorphonuclear Leucocytes in Diabetes Mellitus

1995

Considering the role played by platelets and leucocytes in diabetic disease and keeping in mind the strong correlation between functional and metabolic aspects that characterizes this clinical condition, we evaluated, in two groups of diabetics, respectively the platelet and polymorphonuclear (PMN) cytosolic Ca2+ content (employing the fluorescent probe Fura 2-AM) and membrane fluidity (using the fluorescent probe TMA-DPH and considering the fluorescence polarization degree, inversely related to the membrane fluidity). From the obtained results, it is evident that the platelet cytosolic Ca2+ content does not distinguish normals from diabetics of type 1 and 2; the platelet membrane fluidity …

AdultBlood Plateletsmedicine.medical_specialtyAdolescentMembrane FluidityNeutrophilsEndocrinology Diabetes and MetabolismMetabolic aspectsClinical BiochemistryBiochemistryCytosolEndocrinologyDiabetes mellitusInternal medicineDiabetes MellitusmedicineMembrane fluidityHumansPlateletAgedFluorescent DyesChemistryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseasePLATELET MEMBRANE FLUIDITYCytosolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2CalciumFluorescence anisotropyHormone and Metabolic Research
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct